STAT+: Roche drug sets new standard for KRAS-driven lung cancer

STAT PlusNewsletterThe Readout Roche drug sets new standard for KRAS-driven lung cancer Biotech’s bull market, Vertex’s gene therapy expansion, and more news from The Readout Manage alerts for this article Email this article Share this article By Meghana Keshavan and Andrew JosephJuly 2, 2026 Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter.Andrew Joseph[email protected]Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hi! As ever, lots going on in the light-speed world of biotech. The sector’s rally is gathering steam, the FDA’s AI flexibility is getting lost in translation, and Democrats lose a seasoned biopharma policymaker. Advertisement But I’m still reeling from that synthetic biology SpudCell Matt Herper wrote about. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Andrew Joseph Europe Correspondent Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Adam's Biotech Scorecard July 2, 2026 STAT Plus: Halfway into the year, biotech is booming Health tech July 2, 2026 STAT Plus: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrong Advertisement Biotech July 2, 2026 STAT Plus: A year after distressed buyout, what’s become of Bluebird Bio? In the Lab July 1, 2026 STAT Plus: Synthetic biology researchers think they’ve made a cell. Is it alive? The Readout July 1, 2026 STAT Plus: More signs that GLP-1s may help with peripheral artery disease Subscriber Picks